Zobrazeno 1 - 10
of 101
pro vyhledávání: '"complicated skin and soft tissue infections"'
Publikováno v:
Клиническая микробиология и антимикробная химиотерапия, Vol 26, Iss 1, Pp 40-58 (2024)
Сeftaroline fosamil is a fifth-generation cephalosporin and a unique β-lactam and the only currently registered in the Russian Federation cephalosporin with activity against MRSA. Сeftaroline is approved for use in pediatric practice for the treat
Externí odkaz:
https://doaj.org/article/55697707230c4ae49e74e39d99e12c2f
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Objective In the present study, we aimed to compare the clinical efficacy and safety of omadacycline (OMC) with its comparators for the treatment of complicated skin and soft tissue infections (cSSTIs) in adult patients. Methods Randomized c
Externí odkaz:
https://doaj.org/article/92c50de3a33b4640856c14023147364b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Aura Rusu, Ioana-Andreea Lungu
Publikováno v:
Romanian Journal of Pharmaceutical Practice, Vol 13, Iss 3, Pp 121-126 (2020)
Cephalosporins are beta-lactam antibiotics classified into five generations. The newest generation has three representatives: ceftaroline fosamile, the combination ceftolozane/tazobactam (cephalosporin/beta-lactamase inhibitor), and ceftobiprole medo
Externí odkaz:
https://doaj.org/article/69e074ec4ccd41448abbda08a52608e0
Autor:
Miguel Sánchez-García, Jennifer Hammond, Jean Li Yan, Michal Kantecki, Wajeeha Ansari, Matthew Dryden
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 3, Pp 609-623 (2020)
Abstract Aim Exploratory analyses evaluated patient characteristics and outcomes among patients with complicated skin and soft tissue infection (cSSTI) in the phase 3 COVERS study who were admitted to an intensive care unit (ICU). Methods Adults with
Externí odkaz:
https://doaj.org/article/cfcc5b617cf54d3599cd3e2aae72096a
Autor:
A. V. Rodin, O. I. Agafonov
Publikováno v:
Амбулаторная хирургия, Vol 0, Iss 1-2, Pp 80-86 (2019)
The work describes a new antibiotic from the oxazolidinone group – tedizolid. The results of the clinical studies have shown a high efficacy of tedizolid in complicated skin and soft tissue infections. The use of tedizolid phosphate was accompanied
Externí odkaz:
https://doaj.org/article/b8932d2075c341a0ae3f9ca9ca493105
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 12, Pp 4171-4179 (2018)
Mohamed M Ibrahim,1 Abdulla M Abuelmatty,2 Gehan H Mohamed,3 Mohsen A Nasr,4 Amal K Hussein,5 Mohy El Deen Ebaed,6 Hatem A Sarhan5 1Department of Clinical Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt; 2Department of Pharmacy, Jahra H
Externí odkaz:
https://doaj.org/article/0f7f187668144e6bbd5cebf258e0215a
Publikováno v:
Infection and Drug Resistance, Vol Volume 11, Pp 1959-1974 (2018)
Hoe Nam Leong,1 Asok Kurup,2 Mak Yong Tan,3 Andrea Lay Hoon Kwa,4,5 Kui Hin Liau,6 Mark H Wilcox7 1Rophi Clinic, Mount Elizabeth Novena Specialist Centre, Singapore, Singapore; 2Infectious Diseases Care Private Ltd, Mount Elizabeth Medical Centre, Si
Externí odkaz:
https://doaj.org/article/ea56a160b99f41f6b2cd2add905cc091
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 43-59 (2018)
The objective was to evaluate the cost-effectiveness and budget impact of ceftaroline fosamil compared with other intravenous antibiotics with anti-MRSA activity in the treatment of complicated skin and soft tissue infections (cSSTI). The source of d
Externí odkaz:
https://doaj.org/article/b2989bcdb62e4515a356753c3abceadb
Publikováno v:
Romanian Journal of Pharmaceutical Practice, Vol 13, Iss 3, Pp 121-126 (2020)
Cephalosporins are beta-lactam antibiotics classified into five generations. The newest generation has three representatives: ceftaroline fosamile, the combination ceftolozane/tazobactam (cephalosporin/beta-lactamase inhibitor), and ceftobiprole medo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e3f5eea7c1faad8c96582c6ba741d92
https://farma.com.ro/articles/2020.3/RJPhP_2020_3_Art-02.pdf
https://farma.com.ro/articles/2020.3/RJPhP_2020_3_Art-02.pdf